- Home
- MEGL vs ENSC Comparison
MEGL vs ENSC Comparison
Compare MEGL & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEGL
- ENSC
- Stock Information
- Founded
- MEGL 2016
- ENSC 2003
- Country
- MEGL Hong Kong
- ENSC United States
- Employees
- MEGL N/A
- ENSC N/A
- Industry
- MEGL Finance: Consumer Services
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- MEGL Finance
- ENSC Health Care
- Exchange
- MEGL Nasdaq
- ENSC Nasdaq
- Market Cap
- MEGL 7.0M
- ENSC 4.9M
- IPO Year
- MEGL 2022
- ENSC N/A
- Fundamental
- Price
- MEGL $1.55
- ENSC $2.29
- Analyst Decision
- MEGL
- ENSC
- Analyst Count
- MEGL 0
- ENSC 0
- Target Price
- MEGL N/A
- ENSC N/A
- AVG Volume (30 Days)
- MEGL 3.1M
- ENSC 228.7K
- Earning Date
- MEGL 07-07-2025
- ENSC 08-13-2025
- Dividend Yield
- MEGL N/A
- ENSC N/A
- EPS Growth
- MEGL N/A
- ENSC N/A
- EPS
- MEGL N/A
- ENSC N/A
- Revenue
- MEGL $1,645,862.00
- ENSC $6,224,081.00
- Revenue This Year
- MEGL N/A
- ENSC N/A
- Revenue Next Year
- MEGL N/A
- ENSC $1,381.48
- P/E Ratio
- MEGL N/A
- ENSC N/A
- Revenue Growth
- MEGL N/A
- ENSC 256.35
- 52 Week Low
- MEGL $1.02
- ENSC $1.62
- 52 Week High
- MEGL $5.52
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- MEGL 49.86
- ENSC 49.01
- Support Level
- MEGL $1.46
- ENSC $2.02
- Resistance Level
- MEGL $1.85
- ENSC $2.30
- Average True Range (ATR)
- MEGL 0.25
- ENSC 0.10
- MACD
- MEGL -0.02
- ENSC 0.02
- Stochastic Oscillator
- MEGL 8.60
- ENSC 70.97
About MEGL Magic Empire Global Limited
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.